Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Maryland
Clinical trial register · United States · industry-sponsored

Clinical Trials in Maryland, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 151 Florida 150 Arizona 96 Georgia 89 Illinois 70
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca78 Novartis Pharmaceuticals31 Merck Sharp & Dohme LLC29 Eli Lilly and Company28 Pfizer28 Clear sponsor filter
State
California151 Florida150 Arizona96 Georgia89 Illinois70
All 44 states
Target enrolment
to

Trials with a site in Maryland

28 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-08-14
Recruiting
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
NCT07612267Lactation, Inflammatory Bowel Disease
DrugMirikizumab
Eli Lilly and Company
Phase 4
14
Illinois, Iowa, Maryland, New York, Ohio
2026-08-05
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283Opioid Use Disorder
DrugsBuprenorphine·Brenipatide
Eli Lilly and Company
Phase 2
465
Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maryland
2026-02-13
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2026-02-10
Recruiting
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507Schizophrenia
DrugBrenipatide
Eli Lilly and Company
Phase 2
450
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-10
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland
2025-12-08
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Active, closed
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
250
California, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri, New Jersey
2025-11-17
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Arizona, Arkansas, California, Florida, Illinois, Maryland, Massachusetts, New York
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Maryland
2025-10-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942Psoriasis, Overweight or Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Active, closed
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026Psoriatic Arthritis, Overweight or Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-03-06
Active, closed
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706Glioma
DrugsAbemaciclib·Temozolomide
Eli Lilly and Company
Phase 2
45
California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas
2024-10-25
Active, closed
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
160
Georgia, Idaho, Kansas, Louisiana, Maryland, Minnesota, Missouri, Ohio
2023-10-16
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
DrugsVepugratinib·Digoxin·Enfortumab Vedotin·Rosuvastatin
Eli Lilly and Company
Phase 1
677
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2023-01-12
Active, closed
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
NCT04521686Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
DrugsLY3410738·Durvalumab·Gemcitabine·Cisplatin
Eli Lilly and Company
Phase 1
200
Arizona, California, Florida, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2020-10-01
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Arizona, Arkansas, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2019-12-10
Active, closed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703Breast Neoplasms
DrugsAbemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
669
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2014-07-22
Active, closed
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
NCT01594723Neoplasms, Hematologic
Eli Lilly and Company
Phase 2
110
Arkansas, California, Connecticut, Florida, Illinois, Indiana, Kansas, Maryland
2012-05-22
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/maryland

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies with a site in Maryland that also match the filters currently applied.

How many clinical trials are recruiting in Maryland?

14 of the 28 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Maryland), 28 studies
PhaseStudiesRecruitingShare
Phase 315653.6%
Phase 26421.4%
Phase 14214.3%
Phase 43210.7%

Most active sponsors

Lead sponsors with the most studies (Maryland)
Lead sponsorStudiesRecruiting
Eli Lilly and Company2814
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.